Announcement • Mar 27
Zynex Inc Files Form 15 Zynex Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share. Announcement • Jan 24
Zynex, Inc. Announces Board and Committee Changes, Effective, Effective January 22, 2026 Zynex, Inc. On January 22, 2026, the Board of Directors of the Company of Zynex, Inc. (the Company) determined to (i) remove Thomas Sandgaard from all positions he holds with the Company and its subsidiaries, including as Chair and member of the Board, and Chair and member of the Technology Committee of the Board, effective immediately. On January 21, 2026, Mr. Sandgaard was indicted by a federal grand jury for alleged health care and securities fraud related offenses. Following inquiry into and consideration of the accusations and factual claims in the documents charging Mr. Sandgaard, the Board has determined that Mr. Sandgaard has violated the Company’s Code of Business Conduct and Ethics (the “Code of Ethics”) and that it is advisable and in the best interests of the Company and its stockholders to remove Mr. Sandgaard from all positions he holds with the Company. In connection with the removal of Mr. Sandgaard, on January 22, 2026, the Board appointed Steven Dyson, the Company’s Chief Executive Officer and current member of the Board, to serve as Chair of the Board, effective immediately. In addition, on January 22, 2026, the Board approved a decrease in the number of directors constituting the full Board from seven to six directors in accordance with the Company’s Articles of Incorporation and Bylaws, effective immediately. Announcement • Jan 16
Nasdaq Stock Market to Delist Common Stock of Zynex, Inc The Nasdaq Stock Market announced that it will delist the common stock of Zynex, Inc. Zynex, Inc.’s stock was suspended on December 24, 2025 and has not traded on Nasdaq since that time. Announcement • Dec 25
Zynex, Inc.(OTCPK:ZYXI.Q) dropped from NASDAQ Composite Index Zynex, Inc. has been dropped from the NASDAQ Composite Index . Announcement • Dec 21
Nasdaq Determines to Delist Zynex, Inc.'s Common Stock On December 17, 2025, Zynex, Inc. received a written notice (the Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined to delist the Company's common stock as a result of the Chapter 11 Cases. Pursuant to Nasdaq listing rules, the Company has the right to appeal Nasdaq's delisting determination. The Notice further advises that Nasdaq will suspend trading of the Company's common stock at the opening of business on December 24, 2025 and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the SEC") to effect the delisting of the Company's common stock unless the Company requests an appeal of this determination. The Company does not intend to appeal this determination. The Company anticipates that following suspension from trading, its common stock will commence trading on one of the markets operated by OTC Markets Group. The Company can provide no assurance that the common stock will commence or continue to trade on this market, whether broker-dealers will continue to provide public quotes of the common stock on this market, whether the trading volume of the common stock will be sufficient to provide for an efficient trading market or whether quotes for the common stock will continue on this market in the future. Announcement • Dec 16
Zynex, Inc. Filed for Bankruptcy Zynex, Inc., along with its five affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on December 15, 2025. The debtor listed both its assets and liabilities in the range of $50 million to $100 million. The debtor is represented by Omar Jesus Alaniz of Reed Smith, LLP, and Simpson Thacher & Bartlett LLP as its legal counsels. The debtor also hired Province LLC as its financial advisor, and Epiq Corporate Restructuring, LLC as its claims, noticing, and solicitation agent. Announcement • Nov 13
Zynex, Inc. announced delayed 10-Q filing On 11/12/2025, Zynex, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Oct 15
Zynex, Inc. Announces Management Changes On October 7, 2025, the Board of Directors of Zynex, Inc. (the “Company”) approved an increase in the number of directors constituting the full Board of Directors from five to six and elected Bret W. Wise to fill the vacancy created by such increase, effective October 7, 2025, to serve for a term expiring at the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified or until the earlier of his resignation or removal. Effective October 7, 2025, Mr. Wise was also appointed to serve as Chair of the Audit Committee of the Board of Directors and will also sit on the Compensation Committee and the Nominating and Governance Committee. Mr. Wise is a retired senior executive with significant operational and financial management experience in the medical device industry. Mr. Wise served as Chair and Chief Executive Officer of Dentsply International from January 2007 through February 2016, and as Executive Chair of Dentsply Sirona from March 2016 through September 2017. From 2002 through 2006, Mr. Wise served in various positions at Dentsply International, including President, Chief Operating Officer, and Chief Financial Officer. Prior to 2002, Mr. Wise was Chief Financial Officer of two publicly traded companies and held various positions of increasing responsibility including audit partner with KPMG. Mr. Wise has previously served on the Board of Directors of IMS Health Inc. and Pall Corporation, and two additional private companies. Mr. Wise currently serves as a member of the Board of Directors of Zest Dental Solutions and as a member of the Clinical Advisory Board of the Kansas City University College of Dental Medicine. On October 8, 2025, Anna Lucsok notified the Company of her decision to resign from her position as Chief Commercial Officer of the Company, effective as of October 10, 2025. Board Change • Sep 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Josh Disbrow was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 23
Zynex, Inc. Announces Executive Changes, Effective September 16, 2025 On September 16, 2025, Anna Lucsok transitioned from serving as the Chief Operating Officer of Zynex. Inc. (the “Company”) to serving as the Company’s Chief Commercial Officer. In connection with her title change, Ms. Lucsok will continue to serve as an executive officer of the Company, but her responsibility for overseeing manufacturing, information technology and regulatory matters was re-allocated within the Company. Announcement • Jul 22
Zynex, Inc. to Report Q2, 2025 Results on Jul 31, 2025 Zynex, Inc. announced that they will report Q2, 2025 results on Jul 31, 2025 Announcement • May 12
Zynex, Inc. Submits FDA Application for its NiCO Laser Pulse Oximeter Zynex, Inc. announced it has submitted a 510(k) application to the U.S. Food and Drug Administration ("FDA") for its NiCO™?, Noninvasive CO-Oximeter device. This submission marks a historic milestone in the evolution of pulse oximetry and a major breakthrough for the Company in its mission to improve the quality of care and patient outcomes through its patient monitoring products. Pulse oximetry is one of the world's largest medical device markets and current devices on the market have long been under scrutiny for their inaccuracy and limitations. Zynex's laser technology enables oxygen levels to be measured accurately for patients with dark skin. In cases of carbon monoxide (CO) poisoning, not only are the measurements non-invasive and results instantaneous, but both oxygen and CO are measured accurately, potentially reducing the need for taking blood samples and having to wait for the lab results. Clinical studies following the COVID-19 pandemic highlighted a long-standing problem with traditional LED-based pulse oximeters dangerously misinterpreting oxygenation levels in individuals with darker skin pigmentation, and in patient populations that suffer from low oxygen perfusion. In response to this pressing public health issue, the FDA issued updated pulse oximetry device recommendations earlier this year urged device manufacturers to address this issue in both existing and new technologies with expanded testing guidelines and higher overall accuracy standards. Highly precise laser technology directly measures fractional blood oxygenation levels, rather than the current LED technology which estimates functional oxygen saturation (SpO2), giving clinicians a more complete, reliable and accurate overview of the patient's real-time oxygenation status. Unlike current LED-based pulse oximeters, laser-based pulse oximetry performance is not skewed by pigments such as melanin or nail polish, resulting in highly trustworthy measurements and eliminating harmful pigmentation bias problems. The real-time display of oxygenated hemoglobin, reduced hemoglobin, carboxyhemoglobin and methemoglobin will assist clinicians in earlier and more accurate detection of hypoxia and hyperoxia, which can save lives, lower costs, and enhance overall patient care efficiency. This FDA 510(k) application submission represents a major milestone in Zynex's commitment to delivering cutting-edge medical devices, demonstrating the Company's dedication to ensuring patients and doctors have access to the latest innovations in medical technology. The estimated accessible market for pulse oximetry monitoring is over $2.8 billion today, growing to $4.3 billion in 2027. Major Estimate Revision • May 06
Consensus revenue estimates fall by 16% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$138.0m to US$116.5m. Forecast losses increased from -US$0.49 to -US$0.783 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target down from US$10.00 to US$6.00. Share price fell 9.0% to US$2.03 over the past week. Price Target Changed • May 01
Price target decreased by 37% to US$6.50 Down from US$10.25, the current price target is an average from 2 analysts. New target price is 223% above last closing price of US$2.01. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$0.92 compared to earnings per share of US$0.094 last year. Reported Earnings • Apr 30
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0 in 1Q 2024). Revenue: US$26.6m (down 43% from 1Q 2024). Net loss: US$10.4m (down US$10.4m from profit in 1Q 2024). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 38%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 37% per year, which means it has not declined as severely as earnings. Announcement • Apr 30
Zynex Inc. Provides Earnings Guidance for Second Quarter of 2025 Zynex Inc. provided earnings guidance for second quarter of 2025. For the quarter, the company expects net revenue of at least $27 million. Loss per share is expected to be $0.20 or better. The Company expects quarterly revenues to increase throughout the year with the usual seasonality typically experienced. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$2.52, the stock trades at a trailing P/E ratio of 25.4x. Average trailing P/E is 29x in the Medical Equipment industry in the US. Total loss to shareholders of 65% over the past three years. Announcement • Apr 22
Zynex, Inc. to Report Q1, 2025 Results on Apr 29, 2025 Zynex, Inc. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Mar 31
Zynex, Inc., Annual General Meeting, May 15, 2025 Zynex, Inc., Annual General Meeting, May 15, 2025. Location: 9655 maroon circle, englewood, colorado 80112., United States Announcement • Mar 21
Zynex, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses Block & Leviton announces that a securities fraud lawsuit has been filed against Zynex, Inc. and certain of its executives. Investors who have lost money in their Zynex, Inc. investment should contact the firm to learn more about how they might recover those losses. The lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Zynex shipped products, including electrodes, in excess of need; (2) that, as a result of this practice, the Company inflated its revenue; (3) that the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) that, as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to US$2.71, the stock trades at a trailing P/E ratio of 28.9x. Average trailing P/E is 29x in the Medical Equipment industry in the US. Total loss to shareholders of 57% over the past three years. Major Estimate Revision • Mar 18
Consensus revenue estimates fall by 42% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$239.6m to US$139.4m. Forecast loss of -US$0.49, down from profit of US$0.477 per share profit previously. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$17.50 to US$15.00. Share price fell 62% to US$2.65 over the past week. New Risk • Mar 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$92.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.5x net interest cover). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (US$92.7m market cap). Buy Or Sell Opportunity • Mar 12
Now 52% undervalued after recent price drop Over the last 90 days, the stock has fallen 58% to US$3.41. The fair value is estimated to be US$7.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 38%. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Announcement • Mar 12
Zynex Inc. Provides Earnings Guidance for First Quarter of 2025 Zynex Inc. provided earnings guidance for first quarter of 2025. For the quarter, the Company expects net revenue of at least $30 million. Loss per share is expected to be $0.30 per share or better. The Company expects quarterly revenues to increase throughout the year with the usual seasonality typically experienced. The reduction in expenses which were undertaken throughout the second half of 2024 and more aggressively during Quarter one 2025 will show a significant impact on the bottom line in Quarter two and going forward. Announcement • Mar 03
Zynex, Inc. to Report Q4, 2024 Results on Mar 11, 2025 Zynex, Inc. announced that they will report Q4, 2024 results on Mar 11, 2025 Recent Insider Transactions Derivative • Feb 04
Chief Financial Officer notifies of intention to sell stock Daniel Moorhead intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of February. If the sale is conducted around the recent share price of US$7.84, it would amount to US$157k. Since March 2024, Daniel's direct individual holding has decreased from 52.71k shares to 26.30k. Company insiders have collectively sold US$265k more than they bought, via options and on-market transactions in the last 12 months. Announcement • Dec 13
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters Zynex, Inc. announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of California, San Francisco (UCSF) Hypoxia Lab. Zynex's NiCO pulse oximeter utilizes highly precise laser technology to measure blood oxygenation levels directly, as opposed to current pulse oximeter products, which only estimate oxygenation levels using an LED-based technology. LED pulse oximeters have been shown to mismeasure oxygen levels in several populations, most prominently in individuals with darker skin pigmentation. A poster presentation for the study was recently accepted and presented at the ANESTHESIOLOGY 2024 Event hosted by the American Society of Anesthesiologists that took place October 18 - 22 in Philadelphia. The presentation titled, "Laser-Based Pulse Oximetry Eliminates Effects of Skin Pigmentation on SpO2 Measurements," included results from a study conducted under the supervision of Dr. Philip Bickler at the UCSF Hypoxia Lab. Nine darkly pigmented and nine lightly pigmented participants were recruited for this controlled desaturation study. Four NiCO pulse oximeters and two different commercially available LED-based pulse oximeters were used on each participant. Conclusions from the study showed the NiCO pulse oximeter did not demonstrate a bias for dark pigmented participants compared to lightly pigmented participants. By comparison, conventional LED-based pulse oximeters in the present study read falsely higher on darkly pigmented participants, specifically at lower oxygen saturation levels. Announcement • Dec 06
Zynex, Inc. Announces Completion of Its Laser Pulse Oximetry Trial Zynex, Inc. announced that it has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University. Trial completion is a key milestone required by the FDA prior to submission of a 510(k) for clearance to market and sell the NiCO device for clinical use. With the completion of this study, Zynex now turns to final testing to ensure the operational safety of the device prior to 510(k) submission. Zynex's NiCO pulse oximeter utilizes highly precise laser technology to measure blood oxygenation levels directly, as opposed to current pulse oximeter products, which only estimate oxygenation levels using LEDs. LED pulse oximeters have been shown to mismeasure oxygen levels in several populations, most prominently in individuals with darker skin pigmentation. Zynex Monitoring Solutions' NiCO product line is a strategic investment for Zynex to enter the multi-billion dollar pulse oximetry market with entirely new pulse oximetry technology. The Company is confident that the clinical value of NiCO's unparalleled precision, accuracy, and safety will provide the right entry into this market space. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$9.30, the stock trades at a forward P/E ratio of 23x. Average trailing P/E is 37x in the Medical Equipment industry in the US. Total loss to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$10.90 per share. Recent Insider Transactions Derivative • Nov 01
Founder notifies of intention to sell stock Thomas Sandgaard intends to sell 100k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of October. If the sale is conducted around the recent share price of US$8.92, it would amount to US$892k. For the year to December 2017, Thomas' total compensation was 53% salary and 47% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Thomas has owned 16.04m shares directly. Company insiders have collectively sold US$265k more than they bought, via options and on-market transactions in the last 12 months. Buy Or Sell Opportunity • Nov 01
Now 21% undervalued Over the last 90 days, the stock has risen 3.4% to US$8.63. The fair value is estimated to be US$10.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has declined by 22%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings are also forecast to grow by 46% per annum over the same time period. Reported Earnings • Oct 25
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: EPS: US$0.075 (down from US$0.10 in 3Q 2023). Revenue: US$50.0m (flat on 3Q 2023). Net income: US$2.38m (down 34% from 3Q 2023). Profit margin: 4.8% (down from 7.2% in 3Q 2023). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 24%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Oct 25
Zynex, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 Zynex, Inc. provided earnings guidance for the fourth quarter of 2024. For the quarter, the company's revenue is estimated to be at least $53.6 million. Diluted EPS is estimated to be at least $0.09. Announcement • Oct 16
Zynex, Inc. to Report Q3, 2024 Results on Oct 24, 2024 Zynex, Inc. announced that they will report Q3, 2024 results on Oct 24, 2024 Announcement • Sep 03
Zynex, Inc. Obtains FDA Clearance for New Pain Management Device Zynex Inc. announced FDA clearance of its new TensWave device. The TensWave device, by prescription only, builds on Zynex's strong legacy of innovation in pain management. It offers a user-friendly, portable design that can be easily integrated into patients' daily routines. The device aims to provide effective pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which has been clinically proven to reduce chronic and acute pain without needing medication. It is important to note that the TensWave device is not intended to replace NexWave electrotherapy device, which remains the top choice for patients seeking a comprehensive electrotherapy solution but in certain instances, can provide flexibility in dealing with patients' insurance coverage. The TensWave is a complementary product designed for those whose insurance plans exclusively cover TENS therapy. The TensWave is poised to become an essential tool for patients suffering from chronic pain conditions, offering them a safe, effective, and drug-free alternative to pain management. It complements offerings of electrotherapy products, cervical traction, braces, cold/hot therapy and compression devices. This new product clearance by the FDA marks another milestone in Zynex's ongoing mission to improve patient outcomes through innovative medical technology. Recent Insider Transactions • Aug 11
Chief Operating Officer recently sold US$199k worth of stock On the 7th of August, Anna Lucsok sold around 25k shares on-market at roughly US$8.02 per share. This transaction amounted to 59% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Anna's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$8.35, the stock trades at a forward P/E ratio of 23x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total loss to shareholders of 36% over the past three years. Recent Insider Transactions • Aug 01
Chief Financial Officer recently sold US$124k worth of stock On the 30th of July, Daniel Moorhead sold around 15k shares on-market at roughly US$8.24 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Daniel has been a net seller over the last 12 months, reducing personal holdings by US$293k. Major Estimate Revision • Aug 01
Consensus revenue estimates decrease by 11% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$227.0m to US$201.8m. EPS estimate unchanged from US$0.21 per share at last update. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$21.00 to US$17.50. Share price fell 12% to US$9.00 over the past week. Price Target Changed • Jul 27
Price target decreased by 17% to US$17.50 Down from US$21.00, the current price target is an average from 3 analysts. New target price is 96% above last closing price of US$8.93. Stock is down 9.7% over the past year. The company is forecast to post earnings per share of US$0.49 for next year compared to US$0.27 last year. Reported Earnings • Jul 26
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: US$0.038 (down from US$0.092 in 2Q 2023). Revenue: US$49.9m (up 11% from 2Q 2023). Net income: US$1.22m (down 64% from 2Q 2023). Profit margin: 2.4% (down from 7.5% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Announcement • Jul 26
Zynex, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024 Zynex, Inc. provided earnings guidance for the third quarter and for the full year 2024. For third quarter, revenue is estimated to be at least $50.0 million. Diluted EPS is estimated to be at least $0.05.
For the year, the company expects 2024 net revenue of at least $200 million, a 9% increase from 2023. Diluted EPS is expected to be at least $0.20 per share. Announcement • Jul 17
Zynex, Inc. to Report Q2, 2024 Results on Jul 25, 2024 Zynex, Inc. announced that they will report Q2, 2024 results on Jul 25, 2024 Announcement • May 03
Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024 Zynex, Inc. provided earnings guidance for the second quarter of 2024 and reaffirmed for the full year 2024. For quarter 2024, revenue is estimated to be at least $52.0 million, an increase of approximately 16% from second quarter 2023. Diluted EPS is estimated to be at least $0.08.For the year, the company expects 2024 net revenue of at least $227 million, a 23% increase from 2023. Diluted EPS is expected to be at least $0.50 per share, an 85% increase compared to 2023. Price Target Changed • May 02
Price target increased by 8.1% to US$19.88 Up from US$18.38, the current price target is an average from 4 analysts. New target price is 72% above last closing price of US$11.54. Stock is up 23% over the past year. The company is forecast to post earnings per share of US$0.49 for next year compared to US$0.27 last year. Reported Earnings • May 01
First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023) First quarter 2024 results: EPS: US$0 (down from US$0.043 in 1Q 2023). Revenue: US$46.5m (up 10% from 1Q 2023). Net income: US$10.0k (down 99% from 1Q 2023). Profit margin: 0% (down from 3.7% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Apr 20
Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Zynex, Inc. announced that they will report Q1, 2024 results on Apr 30, 2024 Announcement • Apr 02
Zynex, Inc., Annual General Meeting, May 16, 2024 Zynex, Inc., Annual General Meeting, May 16, 2024, at 09:00 Mountain Daylight. Location: the Company’s corporate headquarters at 9655 Maroon Circle Eaglewood Colorado United States Agenda: To elect as directors the four nominees named in the Proxy Statement as directors; to ratify the selection of Marcum LLP as our independent registered public accounting firm to audit the consolidated financial statements of Zynex, Inc. for our fiscal year ending December 31, 2024; and to consider and transact such other business as may be properly brought before the Annual Meeting and any adjournments. Major Estimate Revision • Mar 07
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$232.9m to US$227.4m. EPS estimate also fell from US$0.542 per share to US$0.483 per share. Net income forecast to grow 76% next year vs 16% growth forecast for Medical Equipment industry in the US. Consensus price target up from US$16.23 to US$18.98. Share price fell 5.6% to US$12.73 over the past week. Reported Earnings • Mar 01
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: US$0.27 (down from US$0.44 in FY 2022). Revenue: US$184.3m (up 17% from FY 2022). Net income: US$9.73m (down 43% from FY 2022). Profit margin: 5.3% (down from 11% in FY 2022). Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 33%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Feb 23
Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Zynex, Inc. announced that they will report Q4, 2023 results on Feb 29, 2024 Announcement • Feb 20
Zynex, Inc. Introduces New Products Zynex, Inc. introduced two new therapy products: the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression. The Zynex Pro Hybrid LSO is a versatile 3-in-1 spinal orthosis featuring a modular design that adapts seamlessly to individual patient needs. Engineered for optimal comfort and support, this innovative orthosis facilitates a smooth transition from rehabilitation to recovery, allowing for single brace use throughout the entire process. The Zynex DynaComp cold Compression is a cutting-edge device that combines cold therapy and compression to accelerate recovery anytime, anywhere. Compact and portable, this innovative device offers on-the-go relief for muscle soreness, swelling, and inflammation, empowering individuals to recover faster and get back to their daily activities with ease. Announcement • Feb 06
Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device Zynex, Inc. announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") for the next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device. NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals. The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998. The E-Wave was the most powerful and versatile muscle stimulation device on the market for over two decades and the M-Wave builds on that history of performance with a more intuitive design and additional functionality. The M-Wave is designed to improve the way patients manage their neuromuscular conditions. With advanced features and a user-friendly design, the M-Wave allows patients to be treated quickly in a clinical or home setting. The compact and lightweight design of the M-Wave ensures portability and easy integration into patients' recovery routines. 
